Cornerstone Wealth Group LLC Purchases 137 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cornerstone Wealth Group LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,865 shares of the biopharmaceutical company’s stock after buying an additional 137 shares during the period. Cornerstone Wealth Group LLC’s holdings in Regeneron Pharmaceuticals were worth $2,753,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. KBC Group NV grew its position in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Blue Trust Inc. boosted its stake in Regeneron Pharmaceuticals by 39.8% during the 4th quarter. Blue Trust Inc. now owns 724 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 206 shares during the period. Strategic Investment Advisors MI grew its holdings in Regeneron Pharmaceuticals by 8.8% in the 4th quarter. Strategic Investment Advisors MI now owns 385 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 31 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Regeneron Pharmaceuticals by 22.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,547 shares of the biopharmaceutical company’s stock worth $1,814,000 after buying an additional 474 shares during the period. Finally, Clarendon Private LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $202,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $675.79 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company’s 50-day moving average price is $727.19 and its two-hundred day moving average price is $936.96.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.